Collectively, these data indicated that FAK activation was related to ROS1 inhibitor (crizotinib)-resistance in CDH1-deficient cancer cells, and that FAK inhibition could thus overcome this drug resistance, ultimately leading to synergistic therapeutic effects in these cancers. The gene discussed is PTK2; the disease is cancer.